Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

37.49 +0.40 (+1.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 614,666
Open 37.40
Bid (Size) 35.05 (10)
Ask (Size) 50.00 (1)
Prev. Close 37.09
Today's Range 36.84 - 37.95
52wk Range 27.98 - 50.99
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
-16.52%
-16.52%
1 Month
-2.29%
-2.29%
3 Month
-12.20%
-12.20%
6 Month
-18.14%
-18.14%
1 Year
-3.95%
-3.95%

More News

Read More
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Earnings Scheduled For February 29, 2024
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.